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Abstract 
Background : To determine the levels of coagulation 
factor VII in patients of chronic liver disease. 
Methods:  In this descriptive study sixty known 
patients of chronic liver disease were included. Patients 
were stratified into three groups on the basis of Child-
Pugh scoring system, utilizing ascites, bilirubin, albumin, 
prothrombin time and encephalopathy as markers of 
disease activity. The correlation of Child-Pugh scoring 
system  with factor VII levels was analyzed  
Results:  Majority ( 63.33%) were  males . Mean age was 
50.5 years. Majority of patients  (82%) had deficient  Factor 
VII  levels. Factor VII levels revealed a declining trend 
from Child-Pugh class B to C. 
Conclusion:  Due to its short half-life factor VII level 
can serve as a helpful marker in diagnosing the degree of 
liver damage and as a prognostic indicator during the 
course of treatment.  
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Introduction 
      Chronic liver disease especially liver cirrhosis is a 
major health problem in our set up.1  It can cause 
significant morbidity and mortality but complications 
can be prevented by early diagnosis.2 Liver diseases 
are frequently associated with hematological 
abnormalities, as liver plays central role in hemostasis. 
3 All clotting factors (except von Willebrand’s factor), 
coagulation inhibitors and fibrinolytic proteins are 
synthesized in the liver . 4,5  Both, qualitative and 
quantitative abnormalities in coagulation factors can 
occur as a consequence of liver disease.6 
     Differences in half lives of clotting factors result in 
variability in response of each factor to liver disease.7 
As factor VII has  the shortest half life (6 hrs), it is the 
first clotting factor to fall in liver disease and its 
deficiency has been shown in majority of patients of 
chronic liver disease. 8 
    Factor VII is a vitamin K dependant factor and its 
posttranslational gamma carboxylation can be 
impaired either by deficiency of vitamin K or by lack 
of blood-clotting enzymes in liver disease . 9 Therefore, 
factor VII level can be used as a sensitive indicator to 
assess the severity of liver disease. Factor VII has 
important role in coagulation through the extrinsic 
coagulation pathway. 10 Coagulation is initiated when 
factor VII binds to Tissue Factor after vessel trauma. A 
series of enzymatic reactions, which lead to the 
generation of alpha-thrombin and ultimately to the 
formation of fibrin plug, is initiated by TF/factor VII 
complex. 11,12 
      Factor VII activity can be measured by a functional 
assay based on clotting tests. Plasma levels of factor 
VII in vivo gives a clear indication of the hemostatic 
balance between the extremes of hemorrhage and 
thrombosis.13  Reduced concentration of zymogen 
factor VII antigen and especially activated form of 
factor VII predisposes to prolonged bleeding and thus, 
increase in pro-thrombin time. 
       Pro-thrombin time is the time taken by clot to form 
after tissue injury and it measures the activity of 
extrinsic and common pathway of coagulation (factor 
II, V, VII, X and fibrinogen). As factor VII is 
responsible for initiation of triggering of the clotting 
cascade and therefore, considerable amount of this 
factor is required for formation of fibrin clots. Its 
deficiency is associated with delayed formation of clot 
and prolongation of pro-thrombin time. So pro-
thrombin time can be considered as a reliable indicator 
of plasma levels of factor VII. 
 
Patients and Methods 
 
    This observational study was carried out on sixty 
diagnosed patients of chronic liver disease admitted in 
gastroenterology department of Military Hospital, 
Rawalpindi, from June 2011 to May 2012. A careful 
history was taken and patients with a history of any 
other coagulation disorder or history of drug intake 
that cause changes in coagulation parameters like oral 
contraceptives, aspirin, heparin, warfarin etc were not 
included in this study. Child-Pugh criteria was  used 
to assess the severity of chronic liver disease and 
patients were categorized according to this criteria 
(Table 1). 
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Patients were divided into three groups depending on 
the severity of chronic liver disease according to Child 
Pugh scoring system, i.e., Group 1: Child-Pugh Class 
A; Group 2: Child-Pugh Class B and Group 3: Child-
Pugh Class C 
     Prothrombin time was measured using appropriate 
and precise proportions of patient’s plasma and 
anticoagulant and factor VII levels were determined 
by using Factor VII deficient plasma in Sysmex CA 
series hematology analyzer.  
 
Table 1: Child-Pugh scoring system to assess the 
severity of chronic  liver disease 
Features Scores Assigned 
 1 2 3 
Ascites -- Slight Moderate 
Bilirubin(mg/dl) < =2 2-3 >3 
Albumin(g/l) >3.5 2.8-3.5 <2.8 
Prothrombin Time 
(seconds) 
1-3 4-6 >6 
Encephalopathy None Grade 1-2 Grade 3-4 
Child-Pugh Class A:  Score of 5;Child-Pugh Class B:  Score 
of 7-9;Child-Pugh Class C:  Score of 10-15 
      
Results 
    A total number of sixty patients of chronic liver 
disease were included in this study. Out of these 38 
(63.3%) were males , with a male to female ratio of 
1.7:1. The age ranged from 22-68 years with a mean 
age of 50.5 years (Table 2).  
          Most common age group was 45-60 years having 
38(63.3%) patients. No patients of age less than 20 
years reported. Twenty two patients were in Group A, 
twenty four in Group B and fourteen in Group C. 
Results and the statistical analysis of factor VII  
showed a trend towards lower values from group A to 
group B and then to group C with a gradual 
prolongation of prothrombin time (Table 2). 
             
Discussion 
          Chronic liver disease progresses to cirrhosis if 
not diagnosed in time and then treated properly. 
Clinical tests including coagulation index are used to 
describe the state of liver disease. Hematological 
derangements in liver disease can be assessed by 
screening tests and coagulation parameters can be 
incorporated into prognostic score for chronic liver 
disease, to be used for assessment of bleeding risk .  As 
in liver disease , synthesis of clotting factors including 
those involved in extrinsic pathway is disturbed and 
thus,  factor VII which is the rate limiting factor for 
this pathway, is affected leading to prolongation of 
pro-thrombin time.14  Investigators have used factor 
VII levels as a tool for specific measurement of hepatic 
synthetic ability in chronic liver disease  as factor VII 
has a short half life and it can be used as a guide to 
severity and prognosis of liver disease.15 
    Strong correlation between factor VII level and 
severity and recovery from liver disease has been 
shown. 16,17  The results of present  study are 
comparable to a study performed by Kujovich(2005)) 
which has demonstrated that factor VII deficiency was 
found in 75%-85% patients of chronic liver disease. 4 
     Factor VII has inverse relationship with pro-
thrombin time so a fall in factor VII level is associated 
with prolongation of prothrombin time. Our study 
showed that prothrombin time is prolonged in chronic 
liver disease depending on the grade of disease. It 
increases progressively from Grade A to B and then to 
C. This finding is similar to the results of a study done 
by Cong et al (2005). 18 
In present  study there was progressive fall in factor 
VII levels with prolongation of prothrombin time and 
this finding is similar to the results of a study done by 
Green et al (1976). 8 Another study by Hameed et 
al(2006)  also showed significant prolongation of pro-
thrombin time with a fall in factor VII levels. 1 
There is a close relationship between severity of liver 
disease and hemostatic changes and the deterioration 
of coagulation functions parallels the severity of liver 
disease.19 
Conclusion 
 
Close monitoring of coagulation parameters is 
required in patients with chronic liver disease , as 
prolongation of these parameters predicts progressing 
disease course and bleeding risk. 
 
Table 2: Mean values of factor VII and Prothrombin time  
Study Variables 
Child Pugh Class- A 
Patients 
Child Pugh Class-B 
Patients 
Child Pugh Class-C 
Patients 
  Range (Mean±S.D)            Range (Mean±S.D) Range (Mean±S.D) 
FactorVII (%activity) 90-158.5 (112.16±21.58)   35.6-79.4 (54.58±11.97)     12.4-36.8 (23.4±8.87)             
Prothrombin Time(Seconds) 13.0 -22.5 (19.8±2.63)             21.7-40.0 (27.2±4.37)         31.4-55.8 (42.20±9.09)           
 
Journal of Rawalpindi Medical College (JRMC); 2013;17(1):25-27 
 
 27 
References 
1. Hameed. A., Naeem. S. Shaikh. S. An assessment of 
coagulation parameters in liver cirrhosis. Biomedica vol 
2006 22: 72-77. 
2. Khan. A.S., Khan. A.R. Changes in fibrinogen level in liver 
cirrhosis. J. Ayyub Coll 2002; 14(2): 19-21. 
3. McHutchison. J.G.  Differential diagnosis of ascites. Semin 
liver Dis 1997; 17(3): 191-202. 
4. Kujovich. J.L. Hemostatic defects in end stage liver disease. 
Crit Care Clin 2005; 21: 563-87. 
5. Castellone D. Liver disease and coagulation outcomes. 
Available at www.aniara.com/Blog/Coagulation-
Corner/archives/2010/11/L. 
6. Northup. P.G., Caldwell. S.H. (ed) .Coagulation disorders in 
cirrhosis---Time for a new clinical paradigm? US 
Gastroenterology Review 2007: 55. 
7. Rodriguez-Inigo. E., Bartolome. J., Quiroga. J.A . Expression 
of factor VII in the liver of patients with liver disease: 
correlations with the disease severity and impairment in the 
hemostasis. Blood Coagul 2001;12: 193-99. 
8. Green. G., Poller. L., Thomson. J.M., Dymock. I.W. Factor VII 
as a marker of hepatocellular synthetic function in liver 
disease. J Clin Pathol 1976;29(11): 971-75. 
9. Deitcher. S.R . Interpretation of international normalized ratio 
in patients with liver disease. Lancet 2002; 359(9300): 47-
48. 
10. Morrissey. J.H. Tissue factor interactions with factor VII: 
measurement and significance of factor VIIa in plasma. 
Blood Coagul Fibrinolysis 1995;6: 14-19. 
11.Rosenberg R.D., Aird W.C. Vascular-bed-specific hemostasis 
and hypercoagulable states. N Engl J Med 1999; 340(20): 
1555-64. 
12. Kalafatis. M., Egan. J.O., van’t Veer. C., Cawthern. K.M. The 
regulation of clotting factors. Crit Rev Eukaryot Gene Expr 
1997; 7(3):241-50. 
13. Li. D., Turner. A., Sinclair. A.J. Plasma coagulation factor VII 
activity and its correlates in healthy men. European Journal 
of Clinical Nutrition 2005; 59: 1423-28. 
14.Tomiya. T., Fujiwara. K. Plasma thrombin – anti-thrombin III 
complexes in the diagnosis of primary hepatocellular 
carcinoma complicating liver cirrhosis. Cancer 1991; 67: 
481-85. 
15. Dymock. I.W., Tucker. J.S., Woolf. I.L., Poller. L. Coagulation 
studies as a prognostic index in acute liver failure. Brit. J. 
Haemat 1975; 29: 385-95. 
16. Gupte. P., Nagral. A. Hematological problems and liver 
disease. Trop Gastroenterol 2009;30(2): 65-70. 
17 Ho. C.H., Hou. M.C., Lin. H.C. . Hemostatic changes in patients 
with liver diseases. Zhongua Yi Xue Za Zhi (Taipei) 1999; 
62(6): 376-82. 
18. Cong. Y.L., Wei. Y.X., Zhang. L.W. The relationship between 
hemostatic changes in liver cirrhosis patients in reference to 
Child-Pugh scores. Zhongua Gau Zanq Bing Za Zi 2005; 
13(1): 31-34. 
19.  Ghumlas AI, Abder AK. Gader. A.G., Al. Faleh. F.Z. 
Haemostatic abnormalities in liver diseases: Could some 
hemostatic tests be useful as liver function tests? Blood 
Coagul. Fibrinolysis 2005; 16(5): 329-35. 
 
